12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 181
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. J. Scott Wolchko | Founder, CEO, President & Director | 920.4k | N/A | 1970 |
Mr. Edward J. Dulac III | Chief Financial Officer | 612.5k | N/A | 1976 |
Ms. Cindy R. Tahl J.D. | General Counsel, Corporate Secretary & Compliance Officer | 612.5k | N/A | 1973 |
Dr. Bahram Valamehr Ph.D. | Chief Research & Development Officer | 644.5k | N/A | 1977 |
Mr. Jim Beitel M.B.A. | Senior Vice President of Corporate Development | N/A | N/A | N/A |
Dr. Jerome Bressi Ph.D. | Senior Vice President of Regulatory & Quality | N/A | N/A | N/A |
Dr. Barbara Hickingbottom | Senior VP of Clinical Development | N/A | N/A | N/A |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 7.